Back to today’s briefing

Story perspectives

LSD Shows Promise in Reducing Anxiety, FDA Fast-Tracks Development

9/4/2025

30 3

Summary

Story summary

A MindMed study found LSD significantly reduced anxiety symptoms in generalized anxiety disorder patients, with effects lasting up to three months.
The 100 microgram dose showed the highest efficacy, achieving nearly 50% remission rates.
The FDA has classified this LSD formulation as a Breakthrough Therapy to expedite its development.
The study seeks to renew interest in psychedelics for mental health treatment in the U.S.

1 of 1

Story summary

A MindMed study found LSD significantly reduced anxiety symptoms in generalized anxiety disorder patients, with effects lasting up to three months.
The 100 microgram dose showed the highest efficacy, achieving nearly 50% remission rates.
The FDA has classified this LSD formulation as a Breakthrough Therapy to expedite its development.
The study seeks to renew interest in psychedelics for mental health treatment in the U.S.